Comparison of sirolimus and colchicine treatment on the development of peritoneal fibrozis in rats having peritoneal dialysis
- PMID: 25759780
- PMCID: PMC4342121
- DOI: 10.5152/balkanmedj.2015.15183
Comparison of sirolimus and colchicine treatment on the development of peritoneal fibrozis in rats having peritoneal dialysis
Abstract
Background: Continuous ambulatory peritoneal dialysis is a successful treatment modality for patients with end-stage renal disease. Peritoneal fibrosis (PF) is the most critical complication of long-term peritoneal dialysis (PD).
Aims: In our study, we aimed to compare the effects of colchicine and sirolimus on PF induced by hypertonic peritoneal dialysis solutions in rats.
Study design: Animal experiment.
Methods: Twenty-four rats were randomly divided into three groups. The control group received an intraperitoneal injection (ip) of saline. The sirolimus group received the PD solution, plus 1.0 mg/kg/day Rapamune®. The colchicine group received the PD solution ip plus 1.0 mg/kg/day of colchicine. Blood samples were taken to measure the serum levels of VEGF, TGF-β, and TNF-α. Peritoneal tissue samples were taken for histopathological evaluation.
Results: TGF-β and TNF-α values in the sirolimus group were found to be statistically significantly lower than in the control and colchicine groups, but the differences between the control and colchicine groups were not statistically significant. No statistically significant differences were found between the groups regarding the VEGF values. Vascular neogenesis and peritoneal thickness were compared; the values in the sirolimus group were statistically reduced compared to the values in the control group. Mild fibrosis developed in 75% of all animals in the sirolimus group; there was no moderate or severe fibrosis observed. Fibrosis developed to varying degrees in 100% of the animals in the control and colchicine groups.
Conclusion: The present study demonstrates that sirolimus might be beneficial for preventing or delaying the progression of PF and neoangiogenesis. These alterations in the peritoneal membrane may be connected with reduced TNF-α and TGF-β levels.
Keywords: Colchicine; peritoneal dialysis; peritoneal fibrosis; sirolimus.
Figures



Similar articles
-
The effect of colchicine on the peritoneal membrane.Ren Fail. 2006;28(1):69-75. doi: 10.1080/08860220500461286. Ren Fail. 2006. PMID: 16526322
-
The effect of oxidative stress inhibition with trimetazidine on the peritoneal alterations induced by hypertonic peritoneal dialysis solution.J Nephrol. 2003 Mar-Apr;16(2):225-30. J Nephrol. 2003. PMID: 12768069
-
Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum.Adv Perit Dial. 2004;20:31-6. Adv Perit Dial. 2004. PMID: 15384791
-
The Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells From Wharton's Jelly in the Treatment of Rat Peritoneal Dialysis-Induced Fibrosis.Stem Cells Transl Med. 2016 Feb;5(2):235-47. doi: 10.5966/sctm.2015-0001. Epub 2015 Dec 30. Stem Cells Transl Med. 2016. PMID: 26718649 Free PMC article.
-
Inflammation, neoangiogenesis and fibrosis in peritoneal dialysis.Clin Chim Acta. 2013 Jun 5;421:46-50. doi: 10.1016/j.cca.2013.02.027. Epub 2013 Mar 4. Clin Chim Acta. 2013. PMID: 23466603 Review.
Cited by
-
Comparison of anti-peritoneal fibrotic effects between an mTORC1-specific blocker and a PI3K/mTOR dual-blocker.Ren Fail. 2019 Nov;41(1):267-277. doi: 10.1080/0886022X.2019.1596818. Ren Fail. 2019. PMID: 30982374 Free PMC article.
-
Effects of hyperthyroidism on expression of vascular endothelial growth factor (VEGF) and apoptosis in fetal adrenal glands.Eur J Histochem. 2015 Nov 26;59(4):2560. doi: 10.4081/ejh.2015.2560. Eur J Histochem. 2015. PMID: 26708182 Free PMC article.
-
Rapamycin inhibits peritoneal fibrosis by modifying lipid homeostasis in the peritoneum.Am J Transl Res. 2019 Mar 15;11(3):1473-1485. eCollection 2019. Am J Transl Res. 2019. PMID: 30972175 Free PMC article.
References
-
- Sayarlioglu H, Dogan E, Erkoc R, Ozbek H, Bayram I, Sayarlioglu M, et al. The effect of colchicine on the peritoneal membrane. Ren Fail. 2006;28:69–75. - PubMed
-
- Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int. 2000;20:43–55. - PubMed
-
- Van Westrhenen R, Aten J, Hajji N, de Boer OJ, Kunne C, de Waart DR, et al. Cyclosporin A induces peritoneal fibrosis and angiogenesis during chronic peritoneal exposure to a glucose-based, lactate-buffered dialysis solution in the rat. Blood Purif. 2007;25:466–72. - PubMed
-
- Lin CY, Chen WP, Yang LY, Chen A, Huang TP. Persistent transforming growth factor beta 1 expression may predict peritoneal fibrosis in CAPD patients with frequent peritonitis occurrence. Am J Nephrol. 1998;18:513–9. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources